What Is HMG?
HMG (Human Menopausal Gonadotropin) is a combination gonadotropin pharmaceutical containing both FSH and LH activity. Originally extracted from the urine of postmenopausal women — where gonadotropin concentrations are naturally elevated following ovarian decline — modern formulations also include highly purified and recombinant preparations. Unlike synthetic research peptides, HMG is a well-established pharmaceutical class with decades of clinical use in assisted reproductive technology (ART).
In male fertility research, HMG is used to restore spermatogenesis in men with hypogonadotropic hypogonadism or TRT/AAS-induced infertility. Because it provides both FSH and LH activity simultaneously, HMG addresses both Leydig cell testosterone production and Sertoli cell-mediated spermatogenesis — a capability that hCG alone (LH-mimetic only) cannot fully replicate. In female fertility, HMG is used to stimulate multi-follicular development in IVF and ovulation induction cycles.
Mechanism of Action
The FSH component of HMG binds to FSH receptors on Sertoli cells in men (or ovarian granulosa cells in women), initiating intracellular signaling cascades that support spermatogenesis in men or follicle maturation in women. The LH component binds to LH receptors on Leydig cells in men (or ovarian theca cells in women), stimulating testosterone synthesis in men or supporting corpus luteum development and ovulation in women.
In men undergoing TRT or recovering from AAS use, exogenous androgens suppress endogenous LH and FSH via negative feedback on the pituitary, impairing spermatogenesis. HMG bypasses the suppressed pituitary entirely, delivering FSH and LH activity directly to the target tissues — a key mechanistic distinction from Gonadorelin, which acts upstream at the pituitary level and is therefore less reliable when pituitary gonadotroph function is suppressed by exogenous androgens.
HMG, hCG, and Gonadorelin: Key Distinctions
Understanding how HMG differs from its co-administered counterparts is essential for protocol design. These three compounds operate at different points in the reproductive axis:
- hCG (LH-mimetic only): Directly stimulates Leydig cells via LH receptors, restoring intratesticular testosterone and testicular volume. Does not activate FSH receptors — often insufficient alone for complete spermatogenesis restoration.
- HMG (FSH + LH): Provides dual gonadotropin activity. The FSH component directly activates Sertoli cells and spermatogenesis. Most effective when added to hCG protocols where sperm count or quality remains inadequate after hCG alone.
- Gonadorelin (GnRH analog): Acts upstream at the pituitary, stimulating endogenous LH and FSH release. Requires an intact, responsive pituitary and pulsatile dosing. Substantially less reliable than direct gonadotropin therapy when pituitary function is suppressed by exogenous androgens.
Quick Reference
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
HMG provides FSH and LH activity to stimulate Sertoli-cell support and germ-cell development, while HCG activates Leydig-cell LH receptors and maintains intratesticular testosterone. This coordinated gonadotropin approach can address both spermatogenesis and androgenic support, with estradiol, hematocrit, and semen parameters requiring monitoring.
HMG directly supplies gonadotropin activity, whereas enclomiphene blocks hypothalamic estrogen receptors and increases endogenous GnRH, LH, and FSH release. Overlapping stimulation may produce excessive estradiol, headaches, visual symptoms, or unstable gonadotropin levels; endocrine and semen monitoring is warranted.
HMG stimulates follicular or Sertoli-cell function through FSH and LH receptors, while NAD+ supports mitochondrial redox balance, oxidative phosphorylation, and sirtuin-dependent repair. These mechanisms are independent but potentially additive for cellular energy demands, without established evidence that NAD+ improves gonadotropin-induced fertility.
HMG activates gonadal FSH and LH receptors, whereas SS-31 stabilizes cardiolipin and reduces mitochondrial reactive oxygen species. Mitochondrial protection could complement follicular or germ-cell energy metabolism, but reproductive benefits remain unconfirmed and should not substitute for monitoring gonadal response.
HMG stimulates gonadal cells through FSH and LH receptors, whereas glutathione limits reactive oxygen species through thiol-dependent antioxidant systems. Redox protection may support oocyte or sperm environments, but evidence does not establish that glutathione materially increases HMG-driven fertility outcomes.
HMG acts through gonadal FSH and LH receptors, while BPC-157 is investigated for tissue repair, angiogenesis, and VEGF-associated signaling. No validated pharmacodynamic interaction is established, and BPC-157’s effects on ovarian function, spermatogenesis, and reproductive safety remain uncertain.
HMG supplies direct gonadotropin activity, while thymosin alpha-1 modulates dendritic cells, Toll-like receptor signaling, and adaptive immune responses. Their principal pathways are distinct, although immune disease, immunomodulatory treatment, and inflammatory changes may complicate interpretation of reproductive outcomes.
HMG stimulates follicular or Sertoli-cell function through FSH/LH receptors, whereas epitalon is proposed to affect telomerase, circadian regulation, and cellular aging. No established interaction with gonadotropin signaling is known, and claims of improved fertility or ovarian reserve remain experimental.
HMG activates gonadal FSH and LH receptors, while GHK-Cu modulates extracellular-matrix turnover, tissue repair, and inflammatory transcription. These pathways are largely separate but could be complementary for general tissue support; no direct enhancement of folliculogenesis or spermatogenesis has been demonstrated.
HMG directly stimulates gonadal FSH and LH receptors, whereas Selank is studied for GABAergic, anxiolytic, and cytokine-regulating effects. Meaningful direct cross-talk is not established, though stress, sleep, and mood changes can indirectly influence hypothalamic reproductive signaling.
Reported Research Timeline
Timing Note
Spermatogenesis requires ~74 days for a complete sperm cycle. Meaningful improvements in sperm parameters require a minimum 3 months of consistent therapy. Assess response at 3, 6, and 12 months before adjusting dose or protocol.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Quality Indicators
Research Citations
- Balasch J, et al. (2003). Highly purified FSH versus highly purified hMG in ART. Hum Reprod.
- Buchter D, et al. (1998). hCG and HMG treatment of male hypogonadotropic hypogonadism. Eur J Endocrinol.
- Liu PY, et al. (2009). Gonadotropin therapy for male infertility. Clin Endocrinol (Oxf).
- Coward RM, et al. (2013). Anabolic steroid-induced hypogonadism: Diagnosis and treatment. Fertil Steril.